Stock market today: S&P 500 climbs as health care, tech gain; Nvidia earnings loom
Investing.com -- BioMarin Pharmaceutical (TADAWUL:2070) Inc. (NASDAQ:BMRN) shares jumped 4.5% after the biotech company reported second-quarter earnings that significantly exceeded analyst expectations, driven by strong sales of its rare disease treatments.
The rare disease specialist posted adjusted earnings of $1.44 per share for the quarter ended June 30, 2025, far surpassing the analyst consensus of $0.83 per share. Revenue climbed 16% YoY to $825 million, well above analyst estimates of $760.37 million. The company’s VOXZOGO treatment for achondroplasia saw revenue increase 20% compared to the same period last year, while its enzyme therapies portfolio grew 15% YoY.
"We were very pleased with our second quarter performance across all aspects of the business, including strong growth, exciting pipeline progress, and delivery of our business development strategy," said Alexander Hardy, President and Chief Executive Officer of BioMarin.
BioMarin raised its full-year 2025 guidance, now expecting revenue between $3.125 billion and $3.2 billion, compared to its previous forecast of $3.1 billion to $3.2 billion. The company also increased its adjusted earnings outlook to $4.40-$4.55 per share, above the analyst consensus of $4.16.
GAAP net income more than doubled to $241 million from $107 million in the year-ago quarter, while the company’s GAAP operating margin expanded to 33.5% from 16.9% a year earlier.
BioMarin also reported progress with its pipeline, including positive Phase 1 data for BMN 333, its long-acting treatment for achondroplasia, which is expected to move into pivotal studies in 2026. The company recently completed its acquisition of Inozyme on July 1, adding BMN 401, a potential first-in-disease treatment for ENPP1 Deficiency, to its portfolio.
The company generated $185 million in operating cash flow during the quarter, a 55% increase from the same period in 2024, ending the quarter with approximately $1.9 billion in cash and investments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.